Eliem Therapeutics Inc

NASDAQ ELYM

Download Data

Eliem Therapeutics Inc Non-current Liabilities to Total Liabilities Ratio 1 year YoY Change (%) for the quarter ending March 31, 2024: -100.00%

Eliem Therapeutics Inc Non-current Liabilities to Total Liabilities Ratio 1 year YoY Change (%) is -100.00% for the quarter ending March 31, 2024, a -850.81% change year over year. The total non-current liabilities to total liabilities ratio measures the proportion of a company's non-current liabilities to its total liabilities. It is calculated by dividing the total non-current liabilities by the total liabilities. This ratio provides insights into the composition of a company's liabilities and the extent to which it relies on long-term debt and obligations. A higher ratio indicates a greater reliance on non-current liabilities, suggesting potential long-term financial commitments and increased financial risk. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Eliem Therapeutics Inc Non-current Liabilities to Total Liabilities Ratio for the quarter ending March 31, 2023 was 0.06, a 13.32% change year over year.
  • Eliem Therapeutics Inc Non-current Liabilities to Total Liabilities Ratio for the quarter ending March 31, 2022 was 0.05, a 0.00% change year over year.
  • Eliem Therapeutics Inc Non-current Liabilities to Total Liabilities Ratio for the quarter ending March 31, 2021 was 0.00.
NASDAQ: ELYM

Eliem Therapeutics Inc

CEO Mr. Robert W. Azelby M.B.A.
IPO Date Aug. 10, 2021
Location United States
Headquarters 23515 NE Novelty Hill Road, Redmond, WA, United States, 98053
Employees 9
Sector Healthcare
Industry Biotechnology
Description

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Similar companies

MNOV

MediciNova Inc

NA

NA

ANEB

Anebulo Pharmaceuticals Inc

NA

NA

HCWB

HCW Biologics Inc

NA

NA

AVTE

Aerovate Therapeutics Inc

NA

NA

ADAG

Adagene Inc

NA

NA

ACRV

Acrivon Therapeutics Inc. Common Stock

NA

NA

ANTX

AN2 Therapeutics Inc

NA

NA

CYT

Cyteir Therapeutics Inc

NA

NA

IPSC

Century Therapeutics Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email